all

Implicit Bioscience is pleased to announce the commencement of its IC14 COVID-19 clinical trials in the US.

The FDA has designated Brisbane biotech Implicit Bioscience’s biologic IC14 an Orphan Drug for the treatment of motor neurone disease.

The US Department of Defense has funded a USD 735,000 grant entitled “Danger Signalling, Traumatic Brain Injury (TBI), and Epileptogenesis”.

The US Food and Drug Administration has issued a “Study May Proceed” letter approving the commencement of clinical study with…

ALS-MND is our leading clinical program in neurodegeneration; however Parkinson’s and Alzheimer’s disease are also coming into sharp focus with…

On June 3, the US FDA approved an Investigative New Drug (IND) application for IC14 together with remdesivir in 300…

New research published in the world’s leading journal Neurology reports a link between higher levels of an inflammatory marker called sCD14 and…

An Australian immunotherapy drug will receive a huge boost when it is tested with four other new concepts across 54…